
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) dosed first patient in a Phase 2 study evaluating a fixed-dose combination of obeticholic acid (OCA) and bezafibrate (BZF) for the treatment of patients with primary biliary cholangitis (PBC).
The study is expected to recruit approximately 60 patients in the United States.